Table 5.
Association of HIV‐Related Factors With Reactive Hyperemia and FMD
| HIV+All Groups | HIV+Treated Suppressed | |||
|---|---|---|---|---|
| Parameter (Per Increase in SD) | FMD %Estimatea (95% CI) | Reactive Hyperemia %Estimate (95% CI) | FMD %Estimate (95% CI) | Reactive Hyperemia %Estimate (95% CI) |
| CD4 count |
−1.3 (−7.3, 5.0) P=0.67 |
0.4 (−3.7, 4.7) P=0.84 |
−2.4 (−10.1, 5.8) P=0.55 |
−2.0 (−7.7, 4.1) P=0.52 |
| Nadir CD4 count |
−0.8 (−6.9, 5.7) P=0.80 |
−0.9 (−5.8, 4.1) P=0.71 |
−1.5 (−8.5, 6.1) P=0.69 |
−0.8 (−7.1, 5.9) P=0.80 |
| CD8 count |
−6.9 (−12.7, −0.8) P=0.03 |
−2.6 (−7.7, 2.7) P=0.33 |
−5.8 (−12.3, 1.2) P=0.10 |
−6.3 (−12.1, −0.1) P=0.05 |
| CD4/CD8 ratio |
5.8 (−0.7, 12.8) P=0.08 |
2.5 (−2.6, 7.8) P=0.35 |
6.4 (−1.7, 15.2) P=0.12 |
4.2 (−2.5, 11.4) P=0.22 |
| ART duration |
−4.0 (−9.7, 2.0) P=0.19 |
−2.7 (−8.1, 2.9) P=0.34 |
−4.9 (−11.9, 2.5) P=0.19 |
−4.2 (−10.6, 2.7) P=0.22 |
| PI Duration |
−0.9 (−6.6, 5.3) P=0.78 |
−2.2 (−7.2, 3.2) P=0.42 |
0.2 (−6.6, 7.6) P=0.95 |
−2.5 (−8.5, 3.9) P=0.43 |
| NRTI duration |
−5.0 (−10.6, 1.0) P=0.10 |
−3.2 (−8.6, 2.7) P=0.28 |
−6.2 (−12.9, 1.0) P=0.09 |
−5.1 (−11.4, 1.7) P=0.14 |
| NNRTI duration |
−0.1 (−5.7, 5.9) P=0.98 |
−0.6 (−6.3, 5.4) P=0.85 |
−0.1 (−7.1, 7.3) P=0.97 |
−2.1 (−9.0, 5.2) P=0.56 |
| HIV duration |
−3.3 (−8.8, 2.6) P=0.27 |
−2.3 (−7.7, 3.4) P=0.43 |
−1.3 (−7.5, 5.4) P=0.70 |
−1.6 (−8.2, 5.5) P=0.65 |
| Viral load |
1.0 (−4.6, 6.9) P=0.74 |
1.6 (−2.7, 6.2) P=0.47 |
NA | NA |
ART indicates antiretroviral therapy; FMD, flow‐mediated dilation; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitor.
a
Percent estimate represents estimated percentage difference in reactive hyperemia or FMD associated with a doubling of each HIV‐related factor. Each factor of interest was adjusted for age, sex, race, hypertension, diabetes mellitus, hyperlipidemia, smoking. Markers are included individually, not simultaneously.